AbbVie: EPS targets raised for 2024
(CercleFinance.com) - On its quarterly earnings call, healthcare group AbbVie has raised its adjusted EPS guidance range for FY 2024 from $10.
61-10.81 to $10.71-10.91.
It reports adjusted EPS of $2.65 for Q2 2024, down 8.9% y-o-y, despite sales of nearly $14.5bn, up 4.3% as reported.
On an operational basis - i.e., excluding currency effects - revenues rose by 5.6%, notably driven by double-digit growth in its oncology (+12.2%) and neuroscience (+15.2%) portfolios.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
61-10.81 to $10.71-10.91.
It reports adjusted EPS of $2.65 for Q2 2024, down 8.9% y-o-y, despite sales of nearly $14.5bn, up 4.3% as reported.
On an operational basis - i.e., excluding currency effects - revenues rose by 5.6%, notably driven by double-digit growth in its oncology (+12.2%) and neuroscience (+15.2%) portfolios.
Copyright (c) 2024 CercleFinance.com. All rights reserved.